MRUS Stock Discussion

Merus N.V. Description

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
S

SwingScalp over 1 year ago

This is the only Expansion Breakout scan symbol for March 15th.  Looks interesting to me so might take this setup today.

0 Reply
T

TraderMike over 1 year ago

I hope it goes well

0 Reply
S

SwingScalp over 1 year ago

I added several Expansion Pivot Buy scan result symbols from the 15th to my daytrade charts in my broker platform as well.  Thanks.  ROL VERX and TIMB look interesting.

0 Reply
S

SwingScalp over 1 year ago

I should have written the only Bullish - Expansion Breakout scan symbol.

0 Reply